J.P. Morgan lifts Rexel to “overweight” on earnings rebound, data-center tailwinds

J.P. Morgan lifts Rexel to “overweight” on earnings rebound, data-center tailwinds
Source link

J.P. Morgan lifts Rexel to “overweight” on earnings rebound, data-center tailwinds
Source link
Indian banking regulator the Reserve Bank of India (RBI) has granted approval to Emirates NBD Bank (P.J.S.C) to acquire up to 74% stake in RBL Bank, marking a potential shift in ownership and strategic direction. The approval was communicated via a letter dated April 1, 2026, ET had earlier reported, citing sources. The report said…
This week’s SafeMoon price movement is taking place in the 0.00002800-0.00003800 range The price of Litecoin rose to $71.54 on Saturday, reaching a new September high SafeMoon chart analysis This week’s SafeMoon price movement is taking place in the 0.00002800-0.00003800 range. There are no significant changes compared to the previous week. The EMA 200…
One of the most underestimated forces in investing is compounding. Not just price appreciation, but the quiet mechanics working in the background. Dividends buy more shares, which then pay even more dividends. Companies buy back stock, shrinking the share count and making your slice of the business more valuable without you lifting a finger. Over…
Image source: Getty Images Valued at $2.4 billion by market cap, Brookfield Business Partners (TSX:BBU.UN) has trailed the broader markets since its initial public offering in 2016. The TSX stock has returned 70% to shareholders in the last eight years after adjusting for dividend reinvestments. However, it trades 23% below all-time highs, allowing you to buy the dip…
IMNTBCHO the collective action of central banks, gummints and pseudo-Keynesian economists, in indulging in political imperatives (gaslighting the plebeians for electoral advantage), have kicked the can down the road to a ridiculous extent. For sure, this has prevented and/or reduced recessions in the intervening period, but has stifled the best possibility of innovation in the…
You always have to be careful with biotechs, they have plenty of specific risks. PAR is unusual because the drug doesnt need the extensive approval process that applies to new drugs, hence the ease with which they were able to set up a Special Access Scheme and get so many people using Zilosul. I am…